THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 1 filers reported holding THESEUS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21 | -72.7% | 7,832 | -6.4% | 0.00% | – |
| Q2 2023 | $77 | -33.0% | 8,365 | -35.6% | 0.00% | – |
| Q1 2023 | $115 | +161.4% | 12,993 | +45.9% | 0.00% | – |
| Q4 2022 | $44 | -99.8% | 8,904 | +76.0% | 0.00% | – |
| Q3 2022 | $29,000 | 0.0% | 5,060 | -2.5% | 0.00% | – |
| Q2 2022 | $29,000 | -59.7% | 5,192 | -16.4% | 0.00% | – |
| Q1 2022 | $72,000 | – | 6,210 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $31,837,872 | 23.54% |
| Lynx1 Capital Management LP | 761,258 | $6,759,971 | 5.64% |
| Omega Fund Management, LLC | 711,479 | $6,317,934 | 4.12% |
| Orbimed Advisors | 17,233,668 | $153,034,972 | 3.00% |
| Fairmount Funds Management LLC | 1,865,671 | $16,567,158 | 2.85% |
| Nextech Invest Ltd. | 611,310 | $5,428,433 | 2.27% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $19,963,963 | 1.44% |
| VR Adviser, LLC | 770,000 | $6,837,600 | 1.34% |
| Opaleye Management Inc. | 488,100 | $4,334,328 | 1.30% |
| Paradigm Biocapital Advisors LP | 1,505,327 | $13,367,304 | 1.27% |